The invention discloses a
drug for treating middle-
advanced stage esophagus cancer, which comprises the following components in parts by weight: 20-30 parts of
codonopsis pilosula, 10-15 parts of rhizoma atractylodis macrocephalae, 10-15 parts of orange peel, 20-30 parts of
semen coicis, 20-30 parts of Chinese yam, 5-10 parts of liquorice, 10-15 parts of mangnolia
officinalis, 10-15 parts of fructus aurantii, 10-15 parts of radix curcumae, 5-10 parts of
bulbus fritillariae cirrhosae, 10-15 parts of
allium macrostemon, 10-15 parts of fructus trichosanthis, 20-30 parts of radix paeoniae alba, 10-15 parts of agilawood, 10-15 parts of fingered citron, 10-15 parts of
arisaema consanguineum schott, 10-15 parts of radix scrophulariae, 10-15 parts of
pericarpium citri reticulatae, 10-15 parts of
pinellia ternate, 5-10 parts of fructus amomi, 10-15 parts of
inula flower, 10-15 parts of ruddle, 10-15 parts of
lotus petiole, 5-10 parts of
coptis chinensis, 10-15 parts of radix aucklandiae, 10-15 parts of radix aucklandiae, 10-15 parts of
adenophora stricta, 20-30 parts of
rehmannia glutinosa, 10-20 parts of
ophiopogon japonicas, 10-20 parts of
angelica sinensis, 10-15 parts of lalang grass
rhizome, 20-30 parts of
oldenlandia diffusa, 20-30 parts of sculellaria barbata, 1-5 parts of
centipede, 5-10 parts of
buthus martensi kirsch, 10-20 parts of
salvia miltiorrhiza, 10-15 parts of fructus
forsythia, 10-20 parts of manyleaf paris
rhizome, 10-15 parts of peach kernel, 10-15 parts of
flos carthami, 10-15 parts of
frankincense and 10-15 parts of
myrrh. The
drug can achieve the purposes of regulating qi-flowing and eliminating
phlegm for removing stasis, nourishing yin and engendering liquid for removing stasis, and promoting
blood circulation to
remove blood stasis; the effective rate can reach 66%.